argenx NV ADR

About argenx NV ADR

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

How StockWorthy values ARGX

StockWorthy forecasts argenx NV ADR's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from ARGX's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.

Related stocks

Regeneron Pharmaceuticals Inc$REGNModerna Inc$MRNAVivoSim Labs, Inc.$VIVS